Todd Christopher Longsworth's Insider Trades & SAST Disclosures
Todd Christopher Longsworth's most recent trade in NovoCure Ltd was a trade of 2,339 Ordinary Shares done at an average price of $70.1 . Disclosure was reported to the exchange on March 8, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Todd Christopher Longsworth.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 70.10 per share. | 08 Mar 2022 | 2,339 | 62,462 (0%) | 0% | 70.1 | 163,964 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 6,106 | 6,106 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 70.41 per share. | 03 Mar 2022 | 1,973 | 64,801 (0%) | 0% | 70.4 | 138,913 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 03 Mar 2022 | 1,094 | 66,774 (0%) | 0% | 74.5 | 81,501 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Grant, award, or other acquisition of securities at price $ 137.12 per share. | 06 Jul 2021 | 154 | 67,868 (0%) | 0% | 137.1 | 21,117 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 130.81 per share. | 08 Mar 2021 | 2,404 | 67,714 | - | 130.8 | 314,458 | Restricted Share Units |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 137.55 per share. | 04 Mar 2021 | 3,084 | 70,118 | - | 137.6 | 424,217 | Restricted Share Units |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 19,004 | 19,004 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 10,342 | 73,202 | - | 0 | Restricted Share Units | |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 152.05 per share. | 02 Mar 2021 | 2,355 | 62,860 | - | 152.1 | 358,085 | Restricted Share Units |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.10 per share. | 27 Feb 2021 | 5,555 | 65,215 (0%) | 0% | 149.1 | 828,251 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 5,555 | 0 | - | - | Restricted Stock Units | |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 36,396 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.37 per share. | 15 Jan 2021 | 36,396 | 123,474 (0%) | 0% | 14.4 | 523,011 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 171.90 per share. | 15 Jan 2021 | 11,985 | 71,403 (0%) | 0% | 171.9 | 2,060,257 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 171.86 per share. | 15 Jan 2021 | 10,110 | 105,156 (0%) | 0% | 171.9 | 1,737,494 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 171.32 per share. | 15 Jan 2021 | 4,826 | 83,388 (0%) | 0% | 171.3 | 826,781 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 167.77 per share. | 15 Jan 2021 | 3,500 | 92,556 (0%) | 0% | 167.8 | 587,209 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 177.33 per share. | 15 Jan 2021 | 2,841 | 61,760 (0%) | 0% | 177.3 | 503,797 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 171.18 per share. | 15 Jan 2021 | 2,761 | 115,266 (0%) | 0% | 171.2 | 472,639 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 169.93 per share. | 15 Jan 2021 | 2,542 | 88,214 (0%) | 0% | 169.9 | 431,970 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 174.06 per share. | 15 Jan 2021 | 2,502 | 67,201 (0%) | 0% | 174.1 | 435,506 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 167.76 per share. | 15 Jan 2021 | 2,499 | 120,975 (0%) | 0% | 167.8 | 419,235 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 175.28 per share. | 15 Jan 2021 | 2,200 | 65,001 (0%) | 0% | 175.3 | 385,614 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 177.30 per share. | 15 Jan 2021 | 2,200 | 97,956 (0%) | 0% | 177.3 | 390,071 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 169.76 per share. | 15 Jan 2021 | 2,148 | 118,027 (0%) | 0% | 169.8 | 364,644 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 169.19 per share. | 15 Jan 2021 | 1,800 | 90,756 (0%) | 0% | 169.2 | 304,549 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 173.10 per share. | 15 Jan 2021 | 1,700 | 69,703 (0%) | 0% | 173.1 | 294,270 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 175.14 per share. | 15 Jan 2021 | 1,700 | 100,556 (0%) | 0% | 175.1 | 297,731 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 173.88 per share. | 15 Jan 2021 | 1,600 | 102,256 (0%) | 0% | 173.9 | 278,205 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 172.95 per share. | 15 Jan 2021 | 1,300 | 103,856 (0%) | 0% | 173.0 | 224,838 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 179.30 per share. | 15 Jan 2021 | 1,200 | 59,660 (0%) | 0% | 179.3 | 215,161 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 178.68 per share. | 15 Jan 2021 | 1,000 | 96,956 (0%) | 0% | 178.7 | 178,675 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 178.50 per share. | 15 Jan 2021 | 900 | 60,860 (0%) | 0% | 178.5 | 160,648 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 179.37 per share. | 15 Jan 2021 | 900 | 96,056 (0%) | 0% | 179.4 | 161,431 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 168.80 per share. | 15 Jan 2021 | 800 | 120,175 (0%) | 0% | 168.8 | 135,043 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 175.98 per share. | 15 Jan 2021 | 400 | 100,156 (0%) | 0% | 176.0 | 70,392 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Sale of securities on an exchange or to another person at price $ 176.22 per share. | 15 Jan 2021 | 400 | 64,601 (0%) | 0% | 176.2 | 70,486 | Ordinary Shares |
| NovoCure Ltd | Todd Christopher Longsworth | General Counsel | Grant, award, or other acquisition of securities at price $ 50.41 per share. | 07 Jul 2020 | 325 | 87,078 (0%) | 0% | 50.4 | 16,382 | Ordinary Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges